Want to see KALA full AI Analyst Report?
KALA Stock Chart & Stats
$0.63
$0.04(5.74%)
At close: 4:00 PM EDT
$0.63
$0.04(5.74%)
Day’s Range― - ―
52-Week Range$0.59 - $1,030.00
Previous Close$0.68
Volume76.44K
Average Volume (3M)1.94M
Market Cap
$14.62M
Enterprise Value$94.00
Total Cash (Recent Filing)$8.76M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.90
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.90
Shares Outstanding19,339,787
10 Day Avg. Volume624,022
30 Day Avg. Volume1,940,241
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)32.38
Price to Sales (P/S)0.00
P/FCF Ratio-7.08
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-26.5
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Reduced Leverage (debt At Zero)Total debt shown at zero materially reduces solvency and interest burden risk versus prior years. Lower leverage improves financial optionality, reduces bankruptcy risk, and makes it easier to allocate future financing to R&D or partnerships rather than debt servicing, supporting multi-month runway resilience.
Established Access To Public CapitalAn active S-3 shelf filing and prospectus supplement indicate structured, near-term access to public financing. This legal and procedural readiness is a durable strategic advantage for a pre-revenue biotech, enabling timely capital raises to fund trials or bridge operations without needing new registration delays.
Improving Equity BufferA rising equity balance provides a larger capital buffer against losses and supports issuance or collaborations. Combined with narrowing losses versus earlier years, a positive and growing equity base gives management more flexibility to pursue development milestones or negotiate non-dilutive partnerships over the coming months.
Bears Say
Zero Revenue BaseNo recurring revenue eliminates internal funding from operations and removes any gross-profit runway. Without product sales or licensing income, the company must rely on external financing for R&D and operations, increasing execution risk and making long-term viability contingent on successful capital raises or clinical milestones.
Sustained And Accelerating Cash BurnPersistent negative operating and free cash flow, with deterioration in the latest TTM, shortens financial runway and forces frequent financing. Accelerating burn increases dilution risk and constrains strategic choices, making it harder to commit to multi-stage clinical programs without securing additional capital.
Smaller Balance Sheet And Limited ScaleReduced total assets and a very small team (6 employees) limit internal development capacity and operational redundancy. Limited scale raises execution and timing risk for trials, increases dependence on partners or CROs, and reduces negotiating leverage when sourcing services or structuring collaborations.
KALA BIO News
KALA FAQ
What was KALA BIO’s price range in the past 12 months?
KALA BIO lowest stock price was $0.59 and its highest was $1030.00 in the past 12 months.
What is KALA BIO’s market cap?
KALA BIO’s market cap is $14.62M.
When is KALA BIO’s upcoming earnings report date?
KALA BIO’s upcoming earnings report date is Aug 06, 2026 which is in 4 days.
How were KALA BIO’s earnings last quarter?
KALA BIO released its earnings results on May 19, 2026. The company reported -$0.136 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is KALA BIO overvalued?
According to Wall Street analysts KALA BIO’s price is currently Overvalued.
Does KALA BIO pay dividends?
KALA BIO does not currently pay dividends.
What is KALA BIO’s EPS estimate?
KALA BIO’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does KALA BIO have?
KALA BIO has 19,339,787 shares outstanding.
What happened to KALA BIO’s price movement after its last earnings report?
KALA BIO reported an EPS of -$0.136 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.642%.
Which hedge fund is a major shareholder of KALA BIO?
Currently, no hedge funds are holding shares in KALA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
KALA BIO
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
Technical Analysis
Daré Bioscience
―
Vyome Holdings
―
Citius Pharmaceuticals
―
Lexaria Bioscience
―
Exicure
―
Ownership Overview
3.47% Insiders
0.34% Mutual Funds
― Other Institutional Investors
95.05% Public Companies and
Individual Investors